Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial-Reference-Cited by-同舟云学术

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Published:2020-06 Issue:6 Volume:31 Page:798-806
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Paz-Ares L.,Spira A.,Raben D.,Planchard D.,Cho B.C.,Özgüroğlu M.,Daniel D.,Villegas A.,Vicente D.,Hui R.,Murakami S.,Spigel D.,Senan S.,Langer C.J.,Perez B.A.,Boothman A-M.,Broadhurst H.,Wadsworth C.,Dennis P.A.,Antonia S.J.,Faivre-Finn C.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference21 articles.

1. Immune checkpoint blockade: a common denominator approach to cancer therapy;Topalian;Cancer Cell,2015

2. Immune checkpoint inhibitors in non-small cell lung cancer;Herzberg;Oncologist,2017

3. Fundamental mechanisms of immune checkpoint blockade therapy;Wei;Cancer Discov,2018

4. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody;Stewart;Cancer Immunol Res,2015

5. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives;Critical Reviews in Oncology/Hematology;2024-11

3. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

4. ImmunoChemoradiation for Non-Small Cell Lung Cancer: A Meta-Analysis of Factors Influencing Survival Benefit in Combination Trials;International Journal of Radiation Oncology*Biology*Physics;2024-10

5. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors;International Journal of Molecular Sciences;2024-09-06